Welcome to our dedicated page for Glaukos SEC filings (Ticker: GKOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Glaukos Corporation filings document the regulatory record for an ophthalmic pharmaceutical and medical technology company with common stock listed on the New York Stock Exchange under GKOS. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary net sales information, supplemental business summaries, and Regulation FD investor presentations.
The company’s proxy materials provide governance and executive-compensation disclosures, including equity-award and pay-versus-performance information. These filings also identify Glaukos as a Delaware corporation and frame disclosure around its glaucoma, corneal-disorder, and retinal-disease therapies, commercial products, risk disclosures, and public-company reporting obligations.
Glaukos Corp (GKOS) insider sale by Chief Development Officer. The filing shows Tomas Navratil sold a total of 5,142 shares on 09/11/2025 under a Rule 10b5-1 trading plan adopted June 12, 2025, at weighted average prices of $87.98 and $88.61. Following these transactions the reporting person beneficially owned 75,469 shares, which include 42,589 restricted stock units that have not vested or been delivered. The filing discloses the sales were executed in multiple trades with price ranges of $87.43–$88.43 and $88.44–$88.88 and states the reporter will provide full trade-by-trade details upon request.
Glaukos Corporation (GKOS) filed a Form 144 reporting a proposed sale of 5,142 common shares, acquired through restricted stock vesting as compensation during March–July 2024. The filing lists an aggregate market value of $453,607.98 for the shares and reports 57,349,987 shares outstanding. The proposed sale date is 09/11/2025 and the broker is listed as Fidelity Brokerage Services LLC on the NYSE. The filer reports no securities sold during the past three months and attests not to possess undisclosed material information.
Glaukos Corporation filed a Form S-8 registration statement to register additional shares of its common stock for issuance under the Glaukos Corporation 2015 Employee Stock Purchase Plan. This filing uses the abbreviated process under General Instruction E to Form S-8, meaning it builds on earlier registration statements for the same plan.
The company incorporates by reference its previously filed Exchange Act reports, so future SEC filings will automatically update this registration. An opinion on the validity of the common stock being registered is provided by Robert Davis, the company’s Senior Vice President, General Counsel and Business Development. The document also includes standard consents, an exhibit index for the ESPP, and signatures from the CEO, CFO, and all directors authorizing the filing.
Wellington Management reports beneficial ownership of 3,244,404 shares of Glaukos Corporation common stock, representing approximately 5.68% of the class. The filing shows no sole voting or dispositive power; voting power is shared for about 2,833,990 shares while shared dispositive power equals the full 3,244,404 shares disclosed.
The securities are owned of record by clients of Wellington investment advisers and are reported as held in the ordinary course of business on a Schedule 13G. Multiple Wellington entities are listed as reporting persons and two classifications appear: several entities as HC (holding companies) and Wellington Management Company LLP as IA (investment adviser).
Glaukos Corporation disclosed that it will present an investor presentation attached as Exhibit 99.1 to this Current Report and that the presentation will be made available on the company’s investor website. The company states the presentation may be used in investor and stakeholder meetings and that the information in Item 7.01 and Exhibit 99.1 is not intended to be deemed filed under the Exchange Act or incorporated by reference in other filings unless explicitly stated.
The report also lists an interactive cover page data file as Exhibit 104. No financial statements, earnings data, or material transactions are included in this filing.